Alpha Cognition Inc. Common Stock (ACOG) Stock Analysis

Alpha Cognition is a commercial-stage biotech focused on Alzheimer’s and neurodegenerative disorders. Its lead product, Zunveyl, is FDA-approved for mild-to-moderate Alzheimer’s dementia and is designed to bypass the GI tract as an inactive prodrug, materially reducing nausea, vomiting, diarrhea, and insomnia that drive discontinuation of legacy therapies. Revenue is generated through U.S. Zunveyl sales and international licensing, including a major China Medical System agreement. The investment case rests on differentiated tolerability, long-term care market penetration, high gross margins, and large global Alzheimer’s demand.